EIF6 and colorectal carcinoma: Furthermore, increasing studies confirm dysregulation of eIF6 has been shown in various cancer entities, such as colorectal carcinoma (CRC) [19], malignant pleural mesothelioma (MPM) [20], ovarian adenocarcinoma (OV) [21], breast cancer (MBC) [22] and non-small cell lung cancer (NSCLC) [23].